PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, Zhuang H, Moser E, Smalley KSM, Lv D, Zhou D, Zheng G, Zhang W.
Wang L, et al. Among authors: tithi ti.
J Exp Med. 2024 Mar 4;221(3):e20231519. doi: 10.1084/jem.20231519. Epub 2024 Feb 9.
J Exp Med. 2024.
PMID: 38334978
Free PMC article.